The question of the administration of @entity172 for therapeutic purposes during climacterium as causing a high frequency of uterine @entity189 is considered. The discussion centers on 7 points of @entity172 therapy. For such therapy in the postmenopausal period there must be clear physical or nervous indications. @entity172 therapy in postmenopause should always be individually prescribed. @entity1 must always be handled on a cyclical basis: this means that there should be a 7-day pause in administration. @entity1 should be well briefed on the signs and symptoms of overdosage. Regualr biannual clinical examinations should be undertaken, with particualr emphasis on the chest and the portio-cervical area. @entity1 should be made aware of the risks of @entity189 with this therapy: certain @entity1 have histories which may indicate a higher risk. In cases of atypical @entity548 an abrasion is certain. If these simple parameters are followed, the risk of @entity189 is likely to be considerably reduced, or at least not of an unforewarned nature.

[Estrogens and XXXX ].

@entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen', 'estrogens', 'Estrogen'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma', 'corpus carcinoma'] @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhaging']
@entity189 :: (MESH:D002277,Disease) :: ['corpus carcinoma']
